動画検索
関連広告
検索結果
Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer. 3.1K views · 6 years ago ...more. OncLiveTV. 23K. Subscribe.
YouTube-OncLiveTV
2018/01/05Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, discusses how to best select ovarian cancer patients who will benefit best ...
YouTube-VJOncology
2023/03/06Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, presents 7-year overall survival results from the Phase III ...
YouTube-VJOncology
2022/09/15Experts review the SOLO-1 trial and olaparib's role as maintenance therapy following the frontline management of ovarian cancer.
YouTube-OncLiveTV
2020/06/03In this segment, Bradley J. Monk, MD; Robert L. Coleman, MD; and Angeles Alvarez Secord, MD, examine the role of poly-ADP ribose polymerase ...
YouTube-OncLiveTV
2015/07/17Are there patients other than BRACA positive who might be candidates for a PARP inhibitor?
Which mutations are eligible for Olaparib?
What are the toxicities associated with OLAPARIB?
How long do you treat patients with Olaparib?
Do you prescribe antiemetics?
Future trials
Are there unique toxicities with olaparib?
Contextual Synthetic Lethality
What do we know about microsatellite instability in ovarian cancer?
What is genomic scarring?
The OlympiA study (NCT02032823) demonstrated the efficacy of olaparib in the treatment of breast cancer patients with germline BRCA 1/2 ...
YouTube-VJOncology
2017/09/21Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic ...
YouTube-U.S. Food and Drug Administration
2024/04/02Prof Paul DiSilvestro, speaks to ecancer about his Phase III SOLO1/GOG-3004 trial which studied the overall survival at 7-year follow-up in ...
YouTube-ecancer
2022/11/29Judy Garber reports on the phase 3 OlympiA study suggesting that adjuvant olaparib could be an option for the treatment of patients with ...
YouTube-Medicine Matters oncology
2021/06/06Jane Robertson, MD, Global Product Vice President for olaparib at AstraZeneca, describes the mechanism of action of olaparib, ...
YouTube-Targeted Oncology
2013/07/30FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients ...
YouTube-U.S. Food and Drug Administration
2024/04/02Share your videos with friends, family, and the world.
YouTube-OncLiveTV
2018/04/25... olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) - 517O: Overall survival (OS) at ...
YouTube-European Society for Medical Oncology (ESMO)
2022/09/20... olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations (gBRCAm) and high-risk HER2-negative early breast cancer ...
YouTube-VJOncology
2021/06/09We're delighted that research has led to a new potential treatment option for people with breast cancer caused by changes in BRCA genes.
YouTube-Breast Cancer Now
2021/07/27In this video, Kathleen Moore, MD, principle investigator, from the Stephenson Cancer Center, Oklahoma City, OK, talks about the ...
YouTube-VJOncology
2018/10/26... Olaparib are PARP-inhibitors that prevent cancer cell repair mechanisms, especially in men with BRCA mutations (20-25% of men). As of now ...
YouTube-Prostate Cancer Research Institute
2020/06/02PCRI's Executive Director, Mark Scholz, MD, describes a clinical trial (NCT03834519) of interest to men with advanced prostate cancer who ...
YouTube-Prostate Cancer Research Institute
2020/01/07動画の見どころ1/6枚目 Background on clinical trials — Clinical trials are an important part of expanding treatment options for men with prostate cancer, and they are generally designed to address an unmet need. In this case, the unmet need is men with advanced prostate cancer who have failed to respond to either Xtandi or Zytiga (but not both) and to chemotherapy. Men in this situation have limited options moving forward.
動画の見どころ2/6枚目 Control (or status quo) arm of the study — The status quo for men in this situation has been to switch to whatever 2nd generation hormone therapy the patient has not yet taken; however, this is usually ineffective. This is the form of therapy that will be given in the control arm of this study
動画の見どころ3/6枚目 Experimental arm of the study — Merck pharmaceuticals is evaluating the efficacy of the combined use of two of its drugs, Lynparza and Keytruda, to compare against the control arm of the study. Both medicines are FDA--approved to treat other forms of cancer.
動画の見どころ4/6枚目 Background on the agents used in this study, Lynparza — Lynparza and Keytruda have both been shown to have activity in prostate cancer. Lynparza is especially useful in men with BRCA mutation, however, a BRCA mutation is not necessary to participate in the study. Lynparza has side effects similar to chemotherapy (fatigue, low blood counts) except without hair loss. It comes in the form of a pill and is taken twice a day. Patients on Lynparza need to be monitored as if they were undergoing chemotherapy.
動画の見どころ5/6枚目 Background on the agents used in this study, Keytruda — Keytruda is an immune medication that "takes the brakes" off the entire immune system. It is an infusion every three weeks. It is usually well-tolerated but around 20% of men will experience side effects due to overactivity of the immune system (asthma, diarrhea, rashes).
動画の見どころ6/6枚目 Lynparza and Keytruda are both potent agents and side effects will be an issue, but men who are in the situation to qualify for this trial do not have many other options.
Talia Golan, MD, on #PancreaticCancer: #Olaparib for #BRCA-Mutated Disease #POLOtrial #GI21.
Facebook-The ASCO Post
2021/02/01) of abiraterone with olaparib, or either agent as monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
YouTube-VJOncology
2024/01/26